Neeraja Kambham, MD
Pathology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: California Pacific Medical Center- Van Ness Campus · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kambham’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A55068 · Current
Licensed to practise in California · since 1995 · expires 2027-07-31 · Osmania University, Osmania Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$34,500
Medicare paid this office $34,500 for 126 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Antibody evaluation, each additional single antibody stain procedure | 68 | $13,425 | $25 |
| Electron microscopy for diagnosis | 72 | $4,972 | $69 |
| Special stained specimen slides to examine tissue including interpretation and report | 88 | $2,877 | $11 |
| Pathology examination of tissue using a microscope, intermediate complexity | 75 | $2,754 | $34 |
| Antibody evaluation, initial single antibody stain procedure | 68 | $2,417 | $32 |
See all 10 services
| Antibody evaluation, each additional single antibody stain procedure | 68 | $13,425 | $25 |
| Electron microscopy for diagnosis | 72 | $4,972 | $69 |
| Special stained specimen slides to examine tissue including interpretation and report | 88 | $2,877 | $11 |
| Pathology examination of tissue using a microscope, intermediate complexity | 75 | $2,754 | $34 |
| Antibody evaluation, initial single antibody stain procedure | 68 | $2,417 | $32 |
| Special stained specimen slides to examine tissue, initial procedure | 47 | $1,538 | $31 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 19 | $1,426 | $75 |
| Pathology examination of tissue using a microscope, moderately high complexity | 17 | $1,181 | $69 |
| Special stained specimen slides to examine tissue and frozen preparation of specimen including interpretation and report | 62 | $1,109 | $18 |
| Special stained specimen slides to examine tissue, each additional procedure | 16 | $727 | $25 |
Who their Medicare patients are
126 Original Medicare patients in 2024. Average age 66 · Women 52% · Also on Medicaid 43% · Health risk score 3.18. Sicker patients than 9 in 10 peers; the typical pathology clinician is at 1.55.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 45% · Heart failure 32% · Coronary heart disease 30% · Cancer 21% · Atrial fibrillation 21% · Depression 20% · COPD 13%.
The office billed $459,855, Medicare allowed $44,009 and paid $34,500; for 1,255 services of 20 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 126 | 1,255 | 66 | 3.18 | $459,855 | $34,500 |
| 2023 | 175 | 1,719 | 67 | 2.66 | $452,920 | $49,503 |
| 2022 | 155 | 1,491 | 67 | 2.94 | $312,956 | $42,455 |
| 2021 | 134 | 1,254 | 64 | 3.34 | $224,896 | $36,194 |
| 2020 | 104 | 1,033 | 64 | 2.98 | $169,846 | $31,231 |
| 2019 | 123 | 1,197 | 61 | 3.16 | $189,597 | $35,472 |
| 2018 | 147 | 1,250 | 63 | 2.94 | $194,279 | $36,227 |
| 2017 | 181 | 1,070 | 64 | 2.62 | $175,901 | $33,991 |
| 2016 | 488 | 1,841 | 70 | 1.82 | $325,481 | $62,967 |
| 2015 | 356 | 1,413 | 69 | 1.71 | $275,092 | $57,277 |
| 2014 | 286 | 1,548 | 68 | 1.99 | $285,508 | $57,975 |
| 2013 | 229 | 1,291 | 65 | 2.20 | $230,904 | $48,036 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Antibody evaluation, each additional single antibody stain procedure | 87 | $18,651 | $27 |
| Electron microscopy for diagnosis | 85 | $6,236 | $73 |
| Special stained specimen slides to examine tissue including interpretation and report | 132 | $4,544 | $11 |
| Pathology examination of tissue using a microscope, intermediate complexity | 103 | $4,168 | $35 |
| Antibody evaluation, initial single antibody stain procedure | 88 | $2,998 | $33 |
| Pathology examination of tissue using a microscope, moderately high complexity | 30 | $2,769 | $77 |
| Pathology examination of specimen during surgery, first tissue block | 15 | $2,153 | $58 |
| Special stained specimen slides to examine tissue, initial procedure | 56 | $2,081 | $33 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 21 | $1,558 | $74 |
| Special stained specimen slides to examine tissue and frozen preparation of specimen including interpretation and report | 74 | $1,418 | $19 |
| Special stained specimen slides to examine tissue, each additional procedure | 22 | $1,135 | $26 |
2022: 11 services
| Antibody evaluation, each additional single antibody stain procedure | 74 | $16,116 | $27 |
| Electron microscopy for diagnosis | 69 | $5,080 | $73 |
| Special stained specimen slides to examine tissue including interpretation and report | 120 | $4,058 | $11 |
| Pathology examination of tissue using a microscope, intermediate complexity | 88 | $3,933 | $35 |
| Antibody evaluation, initial single antibody stain procedure | 75 | $2,624 | $34 |
| Pathology examination of tissue using a microscope, moderately high complexity | 28 | $2,345 | $76 |
| Special stained specimen slides to examine tissue, initial procedure | 53 | $1,977 | $32 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 21 | $1,558 | $74 |
| Special stained specimen slides to examine tissue and frozen preparation of specimen including interpretation and report | 65 | $1,345 | $19 |
| Special stained specimen slides to examine tissue, each additional procedure | 21 | $1,181 | $26 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 13 | $1,053 | $81 |
2021: 10 services
| Antibody evaluation, each additional single antibody stain procedure | 54 | $11,533 | $28 |
| Pathology examination of tissue using a microscope, intermediate complexity | 71 | $4,095 | $34 |
| Special stained specimen slides to examine tissue including interpretation and report | 107 | $4,003 | $11 |
| Electron microscopy for diagnosis | 51 | $3,778 | $74 |
| Pathology examination of tissue using a microscope, moderately high complexity | 38 | $3,196 | $78 |
| Special stained specimen slides to examine tissue, initial procedure | 58 | $2,309 | $33 |
| Antibody evaluation, initial single antibody stain procedure | 54 | $1,887 | $34 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 17 | $1,266 | $74 |
| Special stained specimen slides to examine tissue, each additional procedure | 27 | $1,169 | $27 |
| Special stained specimen slides to examine tissue and frozen preparation of specimen including interpretation and report | 49 | $1,054 | $20 |
2020: 10 services
| Antibody evaluation, each additional single antibody stain procedure | 57 | $12,923 | $28 |
| Electron microscopy for diagnosis | 56 | $4,203 | $75 |
| Pathology examination of tissue using a microscope, intermediate complexity | 64 | $2,661 | $37 |
| Special stained specimen slides to examine tissue including interpretation and report | 89 | $2,620 | $11 |
| Antibody evaluation, initial single antibody stain procedure | 59 | $2,174 | $35 |
| Pathology examination of tissue using a microscope, moderately high complexity | 20 | $1,631 | $78 |
| Special stained specimen slides to examine tissue, initial procedure | 37 | $1,348 | $35 |
| Special stained specimen slides to examine tissue and frozen preparation of specimen including interpretation and report | 51 | $1,119 | $22 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 11 | $895 | $81 |
| Special stained specimen slides to examine tissue, each additional procedure | 13 | $470 | $28 |
2019: 11 services
| Antibody evaluation, each additional single antibody stain procedure | 63 | $13,681 | $27 |
| Electron microscopy for diagnosis | 60 | $4,394 | $73 |
| Pathology examination of tissue using a microscope, intermediate complexity | 77 | $3,451 | $36 |
| Special stained specimen slides to examine tissue including interpretation and report | 107 | $2,904 | $11 |
| Antibody evaluation, initial single antibody stain procedure | 65 | $2,412 | $34 |
| Special stained specimen slides to examine tissue, initial procedure | 48 | $1,966 | $34 |
| Pathology examination of tissue using a microscope, moderately high complexity | 19 | $1,558 | $78 |
| Special stained specimen slides to examine tissue, each additional procedure | 27 | $1,352 | $28 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 14 | $1,164 | $83 |
| Special stained specimen slides to examine tissue and frozen preparation of specimen including interpretation and report | 45 | $1,159 | $21 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 14 | $1,107 | $79 |
2018: 10 services
| Antibody evaluation, each additional single antibody stain procedure | 63 | $13,384 | $27 |
| Electron microscopy for diagnosis | 60 | $4,348 | $72 |
| Pathology examination of tissue using a microscope, intermediate complexity | 91 | $3,794 | $35 |
| Special stained specimen slides to examine tissue including interpretation and report | 122 | $3,518 | $11 |
| Pathology examination of tissue using a microscope, moderately high complexity | 36 | $3,007 | $77 |
| Antibody evaluation, initial single antibody stain procedure | 64 | $2,257 | $34 |
| Special stained specimen slides to examine tissue, initial procedure | 55 | $2,114 | $33 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 15 | $1,157 | $77 |
| Special stained specimen slides to examine tissue, each additional procedure | 25 | $803 | $26 |
| Special stained specimen slides to examine tissue and frozen preparation of specimen including interpretation and report | 30 | $667 | $22 |
2017: 8 services
| Antibody evaluation, each additional single antibody stain procedure | 45 | $7,989 | $27 |
| Pathology examination of tissue using a microscope, intermediate complexity | 117 | $6,987 | $35 |
| Electron microscopy for diagnosis | 52 | $3,833 | $72 |
| Pathology examination of tissue using a microscope, moderately high complexity | 37 | $3,529 | $78 |
| Special stained specimen slides to examine tissue, initial procedure | 60 | $2,736 | $33 |
| Special stained specimen slides to examine tissue including interpretation and report | 107 | $2,723 | $11 |
| Antibody evaluation, initial single antibody stain procedure | 45 | $1,588 | $35 |
| Special stained specimen slides to examine tissue, each additional procedure | 28 | $1,337 | $27 |
2016: 13 services
| Pathology examination of tissue using a microscope, intermediate complexity | 380 | $25,929 | $34 |
| Pathology examination of tissue using a microscope, moderately high complexity | 63 | $5,715 | $77 |
| Antibody evaluation, each additional single antibody stain procedure | 41 | $5,436 | $25 |
| Pathology examination of tissue using a microscope, high complexity | 29 | $4,289 | $138 |
| Special stained specimen slides to examine tissue, initial procedure | 104 | $3,733 | $33 |
| Electron microscopy for diagnosis | 52 | $3,616 | $70 |
| Special stained specimen slides to examine tissue, each additional procedure | 37 | $3,158 | $25 |
| Special stained specimen slides to examine tissue including interpretation and report | 98 | $2,539 | $11 |
| Pathology examination of specimen during surgery, first tissue block | 19 | $1,757 | $59 |
| Antibody evaluation, initial single antibody stain procedure | 46 | $1,626 | $34 |
| Special stained specimen slides to identify organisms including interpretation and report | 33 | $1,460 | $25 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 20 | $1,400 | $70 |
| Pathology examination of tissue using a microscope, moderately low complexity | 32 | $333 | $10 |
2015: 14 services
| Pathology examination of tissue using a microscope, intermediate complexity | 188 | $12,820 | $35 |
| Antibody evaluation, initial single antibody stain procedure | 33 | $12,046 | $39 |
| Pathology examination of tissue using a microscope, moderately high complexity | 67 | $8,263 | $79 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 68 | $4,874 | $72 |
| Pathology examination of tissue using a microscope, high complexity | 22 | $3,052 | $139 |
| Pathology examination of specimen during surgery, first tissue block | 22 | $2,900 | $59 |
| Special stained specimen slides to examine tissue, initial procedure | 70 | $2,654 | $33 |
| Electron microscopy for diagnosis | 37 | $2,594 | $70 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 12 | $2,026 | $169 |
| Special stained specimen slides to examine tissue including interpretation and report | 76 | $1,932 | $11 |
| Special stained specimen slides to examine tissue, each additional procedure | 32 | $1,383 | $20 |
| Special stained specimen slides to identify organisms including interpretation and report | 16 | $735 | $25 |
| Pathology examination of tissue using a microscope, moderately low complexity | 28 | $308 | $10 |
| Preparation of tissue for examination by removing any calcium present | 17 | $278 | $12 |
2014: 15 services
| Antibody evaluation, initial single antibody stain procedure | 58 | $20,101 | $38 |
| Pathology examination of tissue using a microscope, intermediate complexity | 142 | $8,694 | $34 |
| Pathology examination of tissue using a microscope, moderately high complexity | 62 | $7,413 | $75 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 68 | $5,450 | $73 |
| Electron microscopy for diagnosis | 60 | $4,144 | $68 |
| Special stained specimen slides to examine tissue including interpretation and report | 126 | $2,939 | $11 |
| Pathology examination of specimen during surgery, first tissue block | 18 | $2,454 | $57 |
| Pathology examination of tissue using a microscope, high complexity | 13 | $1,633 | $126 |
| Immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain | 47 | $1,406 | $27 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 14 | $1,098 | $78 |
| Special stained specimen slides to identify organisms including interpretation and report | 14 | $894 | $25 |
| Immunohistochemistry or immunocytochemistry, per specimen; each additional single or multiplex antibody stain (list separately in addition to code for primary procedure) | 20 | $470 | $11 |
| Pathology examination of tissue using a microscope, moderately low complexity | 13 | $174 | $10 |
| Preparation of tissue for examination by removing any calcium present | 12 | $146 | $11 |
| Pathology examination of tissue using a microscope, limited examination | 11 | $41 | $4 |
2013: 7 services
| Antibody evaluation, initial single antibody stain procedure | 59 | $20,106 | $37 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 66 | $5,641 | $74 |
| Pathology examination of tissue using a microscope, intermediate complexity | 111 | $5,496 | $32 |
| Electron microscopy for diagnosis | 62 | $4,006 | $64 |
| Special stained specimen slides to examine tissue, initial procedure | 50 | $3,324 | $38 |
| Pathology examination of tissue using a microscope, moderately high complexity | 37 | $3,266 | $74 |
| Special stained specimen slides to examine tissue including interpretation and report | 119 | $2,460 | $11 |
Medicaid work
$10,741 in 2024
Medicaid paid $10,741 for 149 billed services this clinician did in 2024, up to 22 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry | 94 | $4,326 |
| TISSUE EXAM BY PATHOLOGIST | 30 | $3,883 |
| Diagnostic electron microscopy | 13 | $2,008 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 12 | $523 |
| 2024 | 149 | 4 | 22 | $10,741 |
| 2023 | 410 | 8 | 23 | $23,205 |
| 2022 | 229 | 4 | 26 | $11,803 |
| 2021 | 336 | 6 | 29 | $19,811 |
| 2020 | 158 | 5 | 18 | $6,047 |
| 2019 | 127 | 2 | 23 | $4,483 |
| 2018 | 154 | 2 | 17 | $5,610 |
See the largest Medicaid services in earlier years
2023
| Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry | 183 | $10,491 |
| Diagnostic electron microscopy | 39 | $5,105 |
| TISSUE EXAM BY PATHOLOGIST | 71 | $2,765 |
| Immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure) | 48 | $1,930 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 32 | $1,333 |
| TISSUE EXAM BY PATHOLOGIST | 12 | $845 |
| Immunofluorescence, per specimen; initial single antibody stain procedure | 13 | $469 |
| Special stain including interpretation and report; histochemical stain on frozen tissue block (List separately in addition to code for primary procedure) | 12 | $269 |
2022
| Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry | 136 | $8,576 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 33 | $1,294 |
| TISSUE EXAM BY PATHOLOGIST | 17 | $974 |
| TISSUE EXAM BY PATHOLOGIST | 43 | $959 |
2021
| Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry | 133 | $8,970 |
| TISSUE EXAM BY PATHOLOGIST | 54 | $3,614 |
| TISSUE EXAM BY PATHOLOGIST | 73 | $2,954 |
| Diagnostic electron microscopy | 13 | $1,978 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 51 | $1,925 |
| Special stain including interpretation and report; histochemical stain on frozen tissue block (List separately in addition to code for primary procedure) | 12 | $370 |
2020
| Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry | 85 | $3,741 |
| TISSUE EXAM BY PATHOLOGIST | 30 | $1,179 |
| Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure | 16 | $494 |
| Immunofluorescence, per specimen; initial single antibody stain procedure | 12 | $368 |
| Special stain including interpretation and report; histochemical stain on frozen tissue block (List separately in addition to code for primary procedure) | 15 | $265 |
2019
| Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry | 82 | $2,801 |
| TISSUE EXAM BY PATHOLOGIST | 45 | $1,682 |
2018
| Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry | 81 | $3,146 |
| TISSUE EXAM BY PATHOLOGIST | 73 | $2,464 |
Money from drug and device companies
$56 in 2025
| 2025 | 1 | 1 | None | $56 |
| 2023 | 1 | 1 | $2,800 | $2,800 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Fabhalta | $56 | 1 payment
|
See the published payment
| Novartis Pharmaceuticals | Meals · 2025-11-18 | Fabhalta | $56 |
See earlier years (2023)
2023: $2,800
| Novartis Pharmaceuticals | None | $2,800 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1801948930
- Licence
- CA A55068California A55068: Current · expires 2027-07-31
- Group
- Stanford Health Care
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A550680
- Taxonomy
- Federal specialty code 207ZP0102X (207ZP0102X); Federal specialty code 207ZP0101X (207ZP0101X)
- Mailing address
- 300 Pasteur Dr Rm L235, Department of Pathology, Stanford, CA, 94305
- NPI first listed
- 2007-01-17
- NPI last updated
- 2024-03-14
- NPI record certified
- 2024-03-14
This is when the NPI record was last certified, not a medical board exam.